 |
11 Diseases |  |
8 Trials |
|
8 Trials |  |
513 News |  |
| «12345678 |
- | Eucrisa (crisaborole) / Pfizer
Phase classification, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Oct 3, 2017
P=N/A, N=40, Not yet recruiting, Sponsor: Wake Forest University Health Sciences
Phase classification: P4 --> P=N/A
- Eucrisa (crisaborole) / Pfizer
Enrollment open: A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis (clinicaltrials.gov) - Sep 27, 2017
P1, N=32, Recruiting, Sponsor: Pfizer
Phase classification: P4 --> P=N/A Not yet recruiting --> Recruiting
- | Eucrisa (crisaborole) / Pfizer, Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, Review, Journal: Therapeutic pipeline for atopic dermatitis: End of the drought? (Pubmed Central) - Sep 22, 2017
The first highly effective mAb for AD, dupilumab, targets the IL-4/IL-13 receptor and was approved in early 2017 in the United States for moderate-to-severe adult AD...Orally administered small-molecule inhibitors that suppress inflammation (targeting chemoattractant receptor-homologous molecules expressed on TH2 lymphocytes, PDE4, the histamine 4 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibitors) are also being studied. Comparing biomarkers with individual responses to experimental agents will help to determine subphenotypes within AD that predict prognosis and treatment responses.
- | Eucrisa (crisaborole) / Pfizer
New P1 trial: A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis (clinicaltrials.gov) - Aug 23, 2017
P1, N=32, Not yet recruiting, Sponsor: Pfizer
- | Eucrisa (crisaborole) / Pfizer
Biomarker, Enrollment open, Biopsy: Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis (clinicaltrials.gov) - Aug 21, 2017
P2a, N=40, Recruiting, Sponsor: Pfizer
Comparing biomarkers with individual responses to experimental agents will help to determine subphenotypes within AD that predict prognosis and treatment responses. Not yet recruiting --> Recruiting
- | Eucrisa (crisaborole) / Pfizer
New P4 trial, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Aug 15, 2017
P4, N=40, Not yet recruiting, Sponsor: Wake Forest University Health Sciences
- | Eucrisa (crisaborole) / Pfizer
Biomarker, New P2a trial, Biopsy: Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis (clinicaltrials.gov) - Jul 28, 2017
P2a, N=40, Not yet recruiting, Sponsor: Pfizer
- | Eucrisa (crisaborole) / Pfizer
Journal: Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. (Pubmed Central) - Apr 29, 2017
P3
Not yet recruiting --> Recruiting Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.
- ||||||| Eucrisa (crisaborole) / Pfizer
Trial completion, Trial primary completion date: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Dec 30, 2015
P3, N=764, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD. Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015
- ||||||| Eucrisa (crisaborole) / Pfizer
Trial completion, Trial primary completion date: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Dec 30, 2015
P3, N=763, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015
- ||||| Eucrisa (crisaborole) / Pfizer
Enrollment closed: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 21, 2015
P3, N=750, Active, not recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015 Recruiting --> Active, not recruiting
- ||||| Eucrisa (crisaborole) / Pfizer
Enrollment closed: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 21, 2015
P3, N=750, Active, not recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Eucrisa (crisaborole) / Pfizer
Trial primary completion date: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Jul 2015
- |||| Eucrisa (crisaborole) / Pfizer
Trial primary completion date: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- |||||||||| Eucrisa (crisaborole) / Pfizer
New P3 trial: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 17, 2014
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
- |||||||||| Eucrisa (crisaborole) / Pfizer
New P3 trial: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 17, 2014
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
- |||| Eucrisa (crisaborole) / Pfizer
Trial completion: Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis (clinicaltrials.gov) - Jun 20, 2013
P2, N=86, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Trial primary completion date: Feb 2015 --> Jul 2015 Active, not recruiting --> Completed
- | Eucrisa (crisaborole) / Pfizer
Trial completion: Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis (clinicaltrials.gov) - Nov 14, 2012
P1/2, N=23, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- | Eucrisa (crisaborole) / Pfizer
New P1/2 trial: Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis (clinicaltrials.gov) - Jul 26, 2012
P1/2, N=23, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
- ||||| Eucrisa (crisaborole) / Pfizer
New P2 trial: Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis (clinicaltrials.gov) - May 17, 2012
P2, N=86, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
- | Eucrisa (crisaborole) / Pfizer, AN2898 / Pfizer
Enrollment change: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 12, 2011
P2, N=46, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Recruiting --> Completed N=80 --> 46
- | Eucrisa (crisaborole) / Pfizer, AN2898 / Pfizer
Trial completion: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 12, 2011
P2, N=46, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
N=80 --> 46 Active, not recruiting --> Completed
- |||| Eucrisa (crisaborole) / Pfizer
Trial completion: AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis (clinicaltrials.gov) - Oct 24, 2011
P2, N=68, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed